Immunotherapies Based on Tumor Classification
All materials on this site are thoughtfully organized by tumor type for your convenience. Our goal is to provide you with comprehensive information and resources about immunotherapy treatments for various types of cancer. Our team of experts continuously updates this website to ensure that you have access to accurate, evidence-based information.
Acute Lymphocytic Leukemia
- Blinatumomab
- Brexucabtagene autoleucel
- Inotuzumab ozogamicin
- Obecabtagene autoleucel
- Tisagenlecleucel
Agnostic
- Dostarlimab-gxly
- Fam-trastuzumab deruxtecan
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
Alveolar Soft Part Sarcoma
- Atezolizumab
Basal Cell Carcinoma
- Cemiplimab
Bile Duct and Gallbladder Cancer
- Durvalumab
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
- Tremelimumab-actl
Bladder Cancer
- Bacillus Calmette-Guérin (BCG)
- Nadofaragene firadenovec-vncg
- Nogapendekin alfa-inbakicept
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
Blastic Plasmacytoid Dendritic Cell Neoplasm
- Tagraxofusp
Breast Cancer
- Fam-trastuzumab Deruxtecan
- Margetuximab-cmkb
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
- Trastuzumab emtansine
Cervical Cancer
- Atezolizumab
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
- Tisotumab vedotin-tftv
Colorectal Cancer
- Ipilimumab
- Ipilimumab/Nivolumab
- Nivolumab
- Nivolumab hyaluronidase-nvhy
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
Cutaneous Squamous Cell Carcinoma
- Cemiplimab
- Cosibelimab
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
Endometrial Cancer
- Dostarlimab-gxly
- Durvalumab
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
- Tremelimumab-actl
Esophageal Cancer
- Ipilimumab
- Ipilimumab/Nivolumab
- Nivolumab
- Nivolumab hyaluronidase-nvhy
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
Gastric Cancer
- Fam-trastuzumab deruxtecan
- Nivolumab
- Nivolumab hyaluronidase-nvhy
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
- Sacituzumab govitecan
Head and Neck Cancer
- Nivolumab
- Nivolumab hyaluronidase-nvhy
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
Hepatocellular Carcinoma
- Atezolizumab
- Durvalumab
- Ipilimumab
- Ipilimumab/Nivolumab
- Nivolumab
- Nivolumab hyaluronidase-nvhy
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
- Tremelimumab-actl
Hodgkin Lymphoma
- Brentuximab vedotin
- Nivolumab
- Pembrolizumab
Lymphoma
- Axicabtagene ciloleucel
- Brexucabtagene autoleucel
- Epcoritamab-bysp
- Glofitamab-gxbm
- Lisocabtagene maraleucel
- Loncastuximab tesirine
- Mosunetuzumab-axgb
- Obinutuzumab
- Pembrolizumab
- Polatuzumab vedotin
- Tafasitamab-cxix
- Tisagenlecleucel
Melanoma
- Atezolizumab (in combination with cobimetinib and vemurafenib)
- IL-2
- Ipilimumab
- Ipilimumab/Nivolumab
- Lifileucel
- Nivolumab
- Nivolumab hyaluronidase-nvhy
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
- Relatlimab/Nivolumab
- T-VEC
- Tebentafusp-tebn
Merkel Cell Carcinoma
- Avelumab
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
- Retifanlimab-dlwr
Mesothelioma
- Ipilimumab
- Ipilimumab/Nivolumab
- Nivolumab
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
Multiple Myeloma
- Belantamab mafodotin
- Ciltacabtagene autoleucel
- Daratumumab
- Elranatamab-bcmm
- Idecabtagene Vicleucel
- Isatuximab-irfc
- Lenalidomide
- Pomalidomide
- Talquetamab-tgvs
- Teclistamab-cqyv
Nasopharyngeal Cancer
- Penpulimab-kcqx
- Toripalimab-tpzi
Non-Small Cell Lung Cancer
- Atezolizumab
- Cemiplimab
- Datopotamab deruxtecan-dlnk
- Durvalumab
- Fam-trastuzumab Deruxtecan
- Ipilimumab
- Ipilimumab/Nivolumab
- Nivolumab
- Nivolumab hyaluronidase-nvhy
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
- Telisotuzumab vedotin
- Tremelimumab-actl
- Zenocutuzumab-zbco
Pancreatic Cancer
- Zenocutuzumab-zbco
Prostate Cancer
- Sipuleucel-T
Small Cell Lung Cancer
- Atezolizumab
- Durvalumab
- Tarlatamab-dlle
- Tremelimumab-actl
Renal Cell Carcinoma
- Avelumab
- IL-2
- Ipilimumab
- Ipilimumab/Nivolumab
- Nivolumab
- Nivolumab hyaluronidase-nvhy
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
Urothelial Carcinoma
- Avelumab
- Enfortumab vedotin
- Nivolumab
- Nivolumab hyaluronidase-nvhy
- Pembrolizumab
- Pembrolizumab and berahyaluronidase alfa-pmph
- Sacituzumab govitecan
Some tests may be required, such as mismatch repair deficiency, HER-2+(IHC 3+) solid tumor.
Some therapeutics require combinations, not monotherapy, for their FDA-approved indications.